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ABSTRACT 
Tight protein-protein interactions (KD < 100 nM) that occur over a large binding interface (> 1,000 
Å2) are highly challenging to disrupt with small molecules.  Successful inhibition of tight 
interactions requires not only high-affinity binding to the protein receptor, but also effective 
mimicry of critical interface residues of the protein ligand.  Here, we explore whether small 
molecules that mimic the interface residues and the binding profile of the native protein ligand can 
enrich commercial libraries for small-molecule inhibitors of tight protein-protein interactions. We 
target the high-affinity single-digit nanomolar protein-protein interaction between the urokinase 
receptor (uPAR) and its serine proteinase ligand urokinase (uPA). We introduce three methods 
for rank-ordering small molecules docked to uPAR: (i) a new fingerprint approach to identify 
compounds that mimic the uPA ligand binding profile to uPAR receptor interface residues; (ii) a 
pharmacophore approach to identify small molecules that mimic the position of uPA interface 
residues; and (iii) a combined fingerprint and pharmacophore approach. The combined use of 
uPA ligand mimicry and binding pattern to uPAR receptor interface residues led to small 
molecules with new chemotypes that inhibited with single-digit micromolar binding affinities and 
excellent ligand efficiencies.  We conducted an analog-by-catalog approach to explore structure-
activity relationships.  We also report the extensive studies that identified several of the initial hits 
as either lacking stability, were thiol reactive, or redox active.  This work suggests that mimicry of 
the ligand interface residue and binding pattern can be an effective strategy to overcome 
limitations of commercial libraries to identify small-molecule starting points for the development 
of potent inhibitors of tight protein-protein interactions. 
  
INTRODUCTION 
 Protein-protein interactions range from weak (Kd > 1000 nM), moderate (100 nM < Kd < 
1000 nM), to tight (Kd < 100 nM).1-3 They are often classified as primary, secondary, or tertiary.4 
Primary interfaces are generally simple, involving a short linear peptide bound to the surface of 
another protein. Secondary interactions consist of an α-helix or β-turn that binds to a well-defined 
cavity of the receptor. Tertiary interactions are more complex, they have large binding interfaces 
often involving several secondary structures such as α-helices and β-strands.  Kastritis and co-
workers found that 68% of the 144 curated protein-protein interactions were both tight and 
occurred over a large binding interface (> 1000 Å2).20  Yet, despite the gradual increase in the 
number of  small-molecule protein-protein interaction inhibitors,21-28 only a handful among them 
are inhibitors of tight protein-protein interactions.  Small-molecule inhibitors of tight interactions 
tend to be much larger than typical drugs, and generally have poor ligand binding efficiencies, 
which could explain the tendency for these compounds to fail in clinical trials.  The development 
of small molecules with higher ligand efficiency that disrupt tight protein-protein interactions could 
expand the number of druggable proteins for the development of therapeutic agents. 
Considering the ever-expanding size of commercial compound libraries, virtual screening 
could provide an avenue for developing chemical starting points that can be turned into potent 
inhibitors of tight protein-protein interactions with high ligand efficiencies.  To the best of our 
knowledge, only one study has used virtual screening to identify hit compounds that target a tight 
interaction that occurs over a large interface.21 The most common approach for discovery of 
protein-protein inhibitors involves fragment-based methods. For Bcl-xL•Bax22 and IL-2•IL2-Rα,23 
fragment-based approaches and synthesis of derivatives to optimize binding to pockets at the 
protein-protein interfaces led to highly potent small-molecule inhibitors of the protein-protein 
interactions. Recently, virtual screening of fragment libraries led to hit compounds and were 
optimized into potent inhibitors of KEAP1•NRF2.24  In the case of uPAR•uPA, we used 
computational screening of commercial databases that led to IPR-803, which binds to uPAR with 
sub-micromolar binding affinity and disrupts the protein-protein interaction with single-digit 
micromolar IC50s.25, 26 The compound was discovered by virtual screening against a set of uPAR 
structures sampled from molecular dynamics simulations. Computational studies that include 
molecular dynamics simulations predicted a binding mode for the compound along with a critical 
salt-bridge interaction with an Arg-5327 residue. Our predicted binding mode and interaction with 
Arg-53 was recently independently confirmed by a crystal structure of an analog of IPR-803 bound 
to uPAR.28 
Historically, most rational approaches for the design of small-molecule inhibitors of 
protein-protein interactions have focused on mimicking the position of amino acids located on the 
protein ligand of a protein-protein interaction *ref.  In fact, several studies have used interface 
residues of the protein ligand of a protein-protein interaction to guide the design of small-molecule 
inhibitors in virtual screening and lead optimization *ref.  The most common approach is based 
on pharmacophore modeling to enrich libraries for compounds that possessed substituents that 
not only adopted the same position as the amino acid side chain, but also possessed similar 
physicochemical properties to the side chain.  This strategy has worked reasonably well, although 
it is worth mentioning that there are no examples to date of small molecules that disrupt tight 
protein-protein interactions that emerged directly from virtual screening.  Another strategy 
consists of finding molecules that bind directly to the receptor with the hope that these compounds 
will disrupt the protein-protein interaction.  This strategy has never led to inhibitors of tight protein-
protein interactions.  This is attributed to the fact that mere binding to the receptor is not sufficient 
and critical residues, sometimes referred to as hot spots, must be engaged.     
Here, we introduce a simple new strategy that enriches chemical libraries based on 
whether small molecules mimic the binding profile of the native protein ligand to individual 
residues on the receptor.  To that end, we define a “fingerprint” for the native protein ligand based 
on its individual interactions with receptor amino acids.  We use this fingerprint to rank-order 
compounds that closely mimic the native protein ligand.  We also consider the strategy of 
combining the fingerprint approach to the standard pharmacophore method that identifies 
molecules that mimic the position of protein ligand amino acids.  We use the tight uPAR•uPA 
protein-protein interaction as a platform to test these methods. We dock a library of commercially-
available compounds to uPAR and rank compounds using hot spots following three different 
methods. Compounds are tested for activity using fluorescence polarization and microtiter-based 
ELISA confirm disruption of the uPAR•uPA interaction. We also test for direct binding with 
microscale thermophoresis. All active hits are tested for thiol reactivity, redox activity, and stability. 
An analog-by-catalog procedure to explore structure-activity relationships led to the selection and 
testing of several derivatives for each hit compound.   
RESULTS 
uPAR•uPA as a Platform to Test Rank-Ordering Methods. The uPAR•uPA interface 
consists primarily of a β-turn on the protein ligand uPA ensconced in a large pocket on the protein 
receptor uPAR, leading to an interaction that is both tight (Kd = 1 nM) and stable (koff = 10-4 s-1) 
(Fig. 1A). Hot-spot residues exist on both uPAR and uPA. In a comprehensive alanine scanning 
study, 15 residues on uPAR resulted in a significant decrease in binding affinity (∆∆G ≥ 1 kcal∙mol-
1) (Fig. 1B and Table S1).44 Many of these hot spots, including Leu-55, Tyr-57, Leu-66, and Leu-
150, are located within the binding pocket of uPAR. Recently, using molecular dynamics (MD) 
simulations followed by free energy calculations, we found residues on uPAR that are engaged 
in strong van der Waals and electrostatic interactions with uPA, but are not considered hot spots; 
these include Arg-53 and Thr-127 (Fig. 1C and Table S2).33 On uPA, the sidechain of five 
residues extend into the hydrophobic pocket of uPAR: Lys-23, Tyr-24, Phe-25, Ile-28, and Trp-30 
(Fig. 1A and Fig. 1D).45 
A New Fingerprint Method to Rank-Order Compounds Based on their Interaction 
with uPAR Hot Spots. Although previous studies have used ligand hot spots to guide the design 
of small-molecule inhibitors, receptor hot spots have been generally ignored.  Here, for the first 
time, we make use of receptor hot spots to select top candidates that emerge from virtual 
screening of chemical libraries.  We introduce a new approach that uses the native ligand to 
identify compounds that mimic the protein ligand’s interaction with receptor hot spots.  To 
accomplish this, we use a fingerprint method summarized in Fig. 2. These fingerprints consist of 
strings of bits with length equal to the number of residues on the protein target, in our case uPAR. 
Each bit in the fingerprint corresponds to the interaction energy between the compound and a 
residue on uPAR.  If the interaction energy between the ligand and the residue is greater than a 
threshold, the value of the bit is assigned to ‘1’. For compounds, the interaction energy consists 
of the computational decomposition energy. A value of ‘1’ is assigned to a bit if the total 
decomposition energy (∆EResidue) is less than -1.0 kcal∙mol-1. For the native protein ligand, uPA, 
we generate two types of fingerprints based on either experimental data or computational 
decomposition energy. The first type of fingerprint is constructed using the experimentally-
determined alanine scanning data of the uPAR•uPA complex (Fig. 1B and Table S1). In this 
fingerprint, a value of ‘1’ is assigned to a bit if the change in free energy following mutation of the 
residue to alanine (∆∆GAlaScan) is greater than 1.0 kcal∙mol-1. The second fingerprint is constructed 
using the decomposition energies from the molecular dynamics simulation of the uPAR•uPA 
complex (Fig. 1C and Table S2). A value of ‘1’ is assigned to a bit if the total decomposition 
energy (∆EResidue) is less than -1.0 kcal∙mol-1. If the threshold is not met, the value of the bit is ‘0’. 
Following the docking of small molecules from commercial libraries to uPAR, a fingerprint 
is generated for each protein-compound structure.  Each of these compound fingerprints is 
compared to the native protein ligand uPA fingerprint.  Compounds with the most similar 
fingerprints to the protein ligand uPA are given higher priority.  We use the Tanimoto distance (Td) 
to compare the similarity between compounds and protein ligand uPA fingerprint (Fig. 2). Td is 
defined as the ratio between the number of bits in the fingerprint where both uPA and the 
compound have a value of ‘1’ over the number of ‘1’ bits in the uPA fingerprint. The fingerprint 
generated from either alanine scanning or energy decomposition only includes positions where 
the corresponding uPA fingerprint has a value of ‘1’. However, the Tanimoto distance does not 
consider the positions of the specific bits when used to rank-order compounds. Similarly, the 
limited length of each fingerprint results in compounds sharing similar Tanimoto distances. In the 
event that the Tanimoto distance of two compounds is equal, the total enthalpy from the MM-
GBSA calculation of the compound (∆EGBTOT) is used to give higher priority to the compound with 
higher predicted binding affinity. 
Application of the Fingerprint Method to Rank-Order Compounds using uPAR Hot 
Spots. We use the uPAR•uPA interaction as a platform to test our fingerprint method to rank-
order compounds based on their interaction with receptor hot spots.  The positions of the residues 
at the uPAR•uPA interface that were used to generate fingerprints are shown in Fig. 3A. Four 
residues on uPAR are present in both the uPA fingerprints based on the experimental alanine 
scanning and the fingerprints from energy decomposition: Leu-55, Leu-66, Leu-150, and His-166. 
We separately rank-order the 5.1 million docked compounds based on their Td value using 
(i) the uPA alanine scanning fingerprint and (ii) the uPA decomposition energy fingerprint. We 
select the top 500 candidates from each type of fingerprint. We examined how these compounds 
bind to each hot spot on uPAR (Fig. 3B). For compounds identified using the uPA fingerprint 
derived from energy decomposition, over 90% of the selected compounds interact favorably with 
Arg-53, Leu-55, Leu-66, Leu-150, and Ala-255. His-166 and Asp-25 interact with 41% and 86% 
of the compounds, respectively. For compounds identified using the uPA fingerprint derived from 
the experimental alanine scanning experimental data, 95% of the selected compounds interact 
with Leu-55, Leu-66, Leu-150, and His-166. Only 36% interacted with Arg-53, a residue that was 
included in the decomposition but not the alanine scanning fingerprint. 
The top 500 compounds from both the energy decomposition and alanine scanning search 
strategies were independently clustered to 50 compounds using hierarchical clustering. Among 
the 50 compounds from each strategy, 29 from the uPA alanine scanning fingerprint and 24 from 
the uPA decomposition energy fingerprint were purchased for experimental validation. The 
fingerprints and MM-GBSA scores of the 29 and 24 compounds from the alanine scanning and 
decomposition energy fingerprints are listed in Table S3 and Table S4, respectively. These 53 
compounds were initially tested for binding to uPAR using a fluorescence polarization (FP) assay 
that we have previously developed (Fig. 3C).31  The assay consists of a fluorescently labeled α-
helical peptide (AE147-FAM) that binds to uPAR at the uPAR•uPA interface.  One compound, 1 
(IPR-2797), whose binding mode is shown in Fig. 3D, inhibited by more than 40%. A 
concentration-dependent study led to a Ki of 7.1 ± 1.2 µM (Fig. 3E). A follow-up study using a 
microtiter ELISA method to analyze the compound inhibition of the uPAR•uPAATF interaction was 
performed. The compound did not show activity in the ELISA even at 100 µM. The predicted 
binding mode of 1 shows that the benzene of the benzofuran moiety overlaps with Phe-25 on uPA 
(Fig. 3D). In addition, a nitrogen in the piperazine ring of the compound is located near the 
positively charged amine on the sidechain of Lys-23.  
We next assessed 1 for both reactivity and stability. The potential for 1 to covalently react 
with cysteine residues of a protein was evaluated using a (E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-
3H-indol-1-ium (MSTI)-based assay.46 The compound did not react with MSTI suggesting that it 
is not thiol reactive (Fig. S1). The compound was tested for redox activity by a Horseradish 
Peroxidase-Phenol Red (HRP-PR) assay and was found to be redox inactive at 100 µM 
concentration (Fig. S2). Compound stability was tested in methanol, phosphate-buffered saline 
(PBS), and in the presence of uPAR by high-performance liquid chromatography-mass 
spectrometry (HPLC-MS). The compound showed the same retention time in HPLC and the mass 
remained the same, indicating that the compound is stable (Fig. S3). 
Starting with the structure of 1, we searched commercially-available libraries for analogs 
to conduct a preliminary structure-activity relationship (SAR) study.  A set of 36 derivatives of 1 
were identified, purchased, and screened at 50 µM using our FP assay (Fig. 4A). Three 
compounds, 2 (IPR-2944), 3 (IPR-2962), and 4 (IPR-2966), showed 75%, 66%, and 82% 
inhibition, respectively (Fig. 4B). The compounds inhibited the uPAR•AE147-FAM interaction in 
a concentration-dependent manner (Fig. 4C), although all were weaker than the parent 
compound. The most potent derivative, 4 (Ki = 8.6 ± 1.1 µM), contains a fluorine atom on the 
aromatic ring of its benzofuran moiety.  
Selecting Rank-Ordered Compounds using uPA Hot Spots. We explore another 
ranking method that strictly uses the hot spots located on the ligand protein to guide the selection 
of compounds.  Our hypothesis is that small molecules docked to uPAR that mimic the sidechain 
position of protein ligand hot spots will disrupt the uPAR•uPA interaction.  At the uPAR•uPA 
interface, the sidechain of five hot-spot residues on uPA extend into the hydrophobic pocket of 
uPAR: Lys-23, Tyr-24, Phe-25, Ile-28, and Trp-30 (Fig. 1A and Fig. 1D). We use a 
pharmacophore approach47, 48 to identify compounds with substituents that occupy the same 
position as the sidechains of these hot-spot residues. This approach consists of searching for 
small molecules that possess substituents that overlap with similar moieties (pharmacophores) 
on the sidechain of amino acids.  For example, a compound that possesses a benzene group that 
occupies the same position as the aromatic ring (pharmacophore) of a tyrosine residue is 
expected to disrupt binding of the residue to uPAR.  The features of the pharmacophore model 
are shown in Fig. 1D. In the pharmacophore model, the ε-amine on Lys-23 was modeled using a 
positive charge, while the benzene rings of Tyr-24 and Phe-25 were modeled using aromatic 
rings. We assigned separate aromatic ring features to the benzene and pyrrole rings on the indole 
of Trp-30.  
For each of the 5.1 million docked compounds to uPAR, we determined whether there 
was an overlap with the defined pharmacophores on uPA. This resulted in 21312, 809846, 
1297014, and 23047 matches for Lys-23, Tyr-24, Phe-25, and Trp-30, respectively. We identified 
1899 compounds that overlapped with 3 of these 4 hot spots, and no compounds that overlapped 
with all four hot spots. These compounds were hierarchically clustered to 200 using atom triplet 
Daylight fingerprints. We identified 130 commercially-available compounds that were purchased. 
These compounds were tested for binding to uPAR using our FP assay (Fig. 5A). In total, 
approximately 1.8 million of the 5.1 million docked compounds overlapped with at least one of the 
pharmacophores corresponding to a hot spot residue on uPA (Fig. 5B). Among compounds that 
overlapped with a single hot spot, 54% and 27% matched the pharmacophores of Phe-25 and 
Tyr-24, respectively. Less than 2% of compounds overlapped with either the Lys-23 or Trp-30 hot 
spots. In contrast, 16% of compounds overlapped with both the Tyr-24 and Phe-25 hot spots. 
We initially tested the 130 compounds for activity using our FP assay at 50 µM. We 
selected six compounds (5-10) that inhibited more than 40% (Fig. 5A). Compounds 5 (IPR-2477), 
6 (IPR-2496), and 9 (IPR-2532) overlapped with Tyr-24, Phe-25, and Trp-30, while compounds 7 
(IPR-2500), 8 (IPR-2529), and 10 (IPR-2565) overlapped with Lys-23, Tyr-24, and Phe-25 (Fig. 
5C). A concentration-dependent study for these compounds led to Ki values that ranged from 6 
to 97 µM. A follow-up study using a microtiter ELISA to analyze the compound inhibition of the 
uPAR•uPAATF interaction was performed.  Although the ELISA cannot be used to obtain inhibition 
constants, it is a useful assay to determine whether compounds bind and disrupt the protein-
protein interaction between uPA and uPAR.  Four compounds, namely 6, 7, 9, and 10 showed 
activity in the ELISA assay with IC50s ranging from 7 to 230 µM.  
We assessed the reactivity and stability of all hit compounds. Compound 6 contains a Betti 
base that may cause the compound to be unstable and reactive, while 10 was thought to have a 
potential activated thiol group (Fig. 5A). The MSTI thiol reactivity assay was performed for each 
of the hits (Fig. S1). Compound 10 readily reacted with MSTI as evidenced by a decrease in the 
fluorescence of MSTI.  Compound 6 displayed no detectable MSTI reactivity, but we suspected 
that this was due to the unstable nature of the compound. The HRP-PR redox activity assay 
showed no significant redox capacity for compounds 5-10 (Fig. S2). At this point, we decided to 
pursue compounds 5, 6, 8, and 9. HPLC-MS stability assay for 8 and 9 showed the same single 
peak for both methanol and PBS buffers, indicating that the compounds were stable (Fig. S3). 
A set of 55 derivatives of 5 were purchased and screened using the FP assay at 50 µM. 
A number of compounds displayed significant inhibition (Fig. S4A). Three compounds (Fig. S4B), 
11 (IPR-2603), 12 (IPR-2605), and 13 (IPR-2606), were chosen to be further studied at several 
concentrations using FP (Fig. S4C) and ELISA (Fig. S4D). Compound 11 displayed better Ki than 
the parent in the FP assay while all three compounds showed activity in the ELISA. MSTI assay 
of these three derivatives detected no thiol reactivity (Fig. S4E), but the reaction might be masked 
by assay interference, as all three compounds are yellow when dissolved in the assay buffer. The 
compounds showed no appreciable redox activity (Fig. S2). However, the HPLC-MS study 
revealed that all the compounds were mixtures as shown for 12 (Fig. S3). This suggests that the 
compound series may be unstable and inhibits through a non-specific mechanism. This is further 
supported by the fact that despite the differences in structure between 11, 12, and 13, the three 
compounds exhibit similar Kis in the FP assay and IC50 in the ELISA. 
Compound 6 was pursued with reservation considering the reactive Betti base. 
Compounds 14-17 were purchased, and we synthesized 18 (IPR-2804) that lacked the hydroxyl 
group of the Betti base (Fig. S5A). Compounds were initially tested at 50 µM and then in a 
concentration-dependent manner using the FP assay and ELISA (Fig. S5B). The compounds 
with the Betti base moiety inhibited substantially, while 18 showed no activity in either assay. The 
complete lack of activity of 18, despite its structural similarity with the parent compound, strongly 
suggested that the activity of 6 and derivatives was non-specific.  This is further confirmed by the 
MSTI assay, which shows 18 to be non-reactive while 14-17 are reactive (Fig. S5C). Compound 
17 (IPR-2665) did not bind to uPAR using microscale thermophoresis (data not shown). To 
determine whether the compounds reacted with uPAATF as well as uPAR, the ELISA setup was 
slightly modified, whereby we pre-incubated immobilized uPAATF with the compounds for 30 min, 
followed by the washing step, which discarded all compounds in the well, followed by addition of 
uPAR. Despite the complete lack of contact of the compound with uPAR, both compounds 6 and 
17 displayed significant inhibition at 50 µM concentration, while our reversible uPAR inhibitor, 
IPR-1109,49 was washed away and did not inhibit (Fig. S5D). This suggested that the compounds 
were also forming adducts with uPA further supporting a non-specific mechanism.  To test for 
specificity, 17 was tested in two other FP assays against TEAD4 transcription factor and voltage-
gated calcium channel β-subunit 3 (CaVβ3) proteins; they inhibited in both assays (Fig. S5E). 
Compounds 6 and 17 showed no redox activity on the HRP-PR assay (Fig. S1). HPLC-MS 
analysis of 6 showed that the compound broke down in methanol and PBS buffer, resulting in 
weak UV signals. This confirmed that the compounds were unstable.  The total ion count 
chromatogram showed three distinct peaks, the intact 6 and two fragments (Fig. S5F).  This 
compound series was not pursued further. 
Compound 8 binds to uPAR with double-digit micromolar affinity (Ki = 37.2 ± 19.8 µM) 
based on the FP assay. The binding mode from the virtual screen shows that the compound’s 
morpholino, methylphenyl, and methoxyphenyl groups overlap with Lys-23, Tyr-24, and Phe-25, 
respectively (Fig. 6A). A search of the ZINC chemical library identified 37 derivatives that were 
purchased and screened at 50 µM using our FP assay (Fig. 6B). Two derivatives, 19 (IPR-2916) 
and 20 (IPR-2922) (Fig. 6C) were chosen and tested by concentration-dependent FP (Fig. 6D) 
and ELISA (Fig. 6E). The compounds showed weak Ki and IC50 values, but they provide a starting 
point for the development of more potent inhibitors of the very tight protein-protein interaction. 
Compound 9 binds to uPAR with affinity near 100 µM (FP Ki = 97.4 ± 61.2 µM, ELISA IC50 
= 230.6 ± 41.7 µM). The virtual screening binding mode of 9 is shown in Fig. 7A.  On one end of 
the compound, the dimethoxybenzene overlaps with Trp-30. On the other end, the acyl 
morpholine is buried into the binding pocket. A benzene ring near this moiety overlaps with Phe-
25, while a pyrimidine in the core overlaps with Tyr-24. A total of 8 derivatives were purchased 
and screened by the single-concentration FP assay (Fig. 7B). None of the derivatives showed 
strong similarity to the parent compound.  As a result, most of these derivatives showed even 
weaker binding and inhibition than 9.  The best compounds were 21 (IPR-2940) and 22 (IPR-
2942) (Fig. 7C), which we tested by concentration-dependent FP (Fig. 7D) and ELISA (Fig. 7E).  
Selecting Rank-Ordered Compounds using both uPA and uPAR Hot Spots. We 
wondered whether combining our fingerprint method with the pharmacophore approach could 
yield small-molecule uPAR•uPA inhibitors. We combined the two search methods to identify a set 
of 69 compounds that overlapped with three of the four hot spots on uPA as well as engage hot 
spots in the uPA binding pocket on uPAR. A set of 39 compounds selected from among the 69 
compounds were purchased for binding studies. The fingerprints and MM-GBSA scores of the 15 
and 24 compounds from the alanine scanning and decomposition energy fingerprints are listed in 
Table S5 and Table S6, respectively. The 39 compounds were tested in our FP assay (Fig. 8A). 
Seven compounds (23-29) were assessed using a concentration-dependent manner to determine 
the Ki values (Fig. 8B). Compounds 23 (IPR-2986), 26 (IPR-2992), 27 (IPR-2993), 28 (IPR-3089), 
and 29 (IPR-3193) overlapped with Lys-23, Tyr-24, and Phe-25 on uPA, while 24 (IPR-2987) and 
25 (IPR-2989) overlapped with Tyr-24, Phe-25, and Trp-30. In comparison to hits that emerged 
from fingerprint or pharmacophore methods, the compounds had better Ki values that ranged from 
6 to 52 µM. Only 25, 26, 28, and 29 inhibited uPAR•uPAATF based on a concentration-dependent 
study using our ELISA.  The compounds had IC50 values of 68.3 ± 11.0, 140.6 ± 19.0, 172.8 ± 
42.5, and 24.8 ± 2.2 µM in the ELISA, respectively. The presence of α,β-unsaturated carbonyls 
on 23, 24 and 27 suggested potential reactivity with residue on uPAR and uPA.  However, none 
of the hits from this screen showed reactivity with the activated thiol of the MSTI compound 
suggesting that the activity of the compounds is unlikely due to covalent bond formation (Fig. 8C). 
Compounds 24 and 27 displayed slight redox capacity in the HRP-PR assay, while compounds 
23, 25, 26, 28, and 29 showed no redox activity (Fig. S2). We focused our attention on 26, 28, 
and 29 as these compounds do not contain any problematic moiety and showed no covalent 
reaction or redox activity.  HPLC-MS analysis of these three compounds (Fig. S3) showed the 
compounds to be stable in both methanol and PBS buffers, with similar retention times. 
Compound 26 binds into the uPAR•uPA pocket, mimicking the hot spot residues of uPA 
and engaging hot spots on uPAR (Fig. 9A). A benzene moiety overlaps with Phe-25 on uPA. In 
the binding mode, a morpholino group is located between Lys-23 and Tyr-24 of uPA. In addition, 
a methyl substituent on the core quinoline ring points towards Trp-30. The core structure of 26 
was used to identify derivatives. The derivatives we identified showed modifications at five 
substituents on 26 (Fig. 9B). A set of 136 derivatives of 26 were purchased and screened at 50 
µM (Fig. 9C). The best hits were tested in concentration-dependent manner and their Kis ranged 
from 2 to 37 µM (Table 1 and Fig. S6). The compounds were further tested in the uPAR•uPAATF 
ELISA assay to determine whether they can inhibit the protein-protein interaction (Table 1 and 
Fig. S7). Only 32 (IPR-3026) and 39 (IPR-3116) failed to inhibit in the ELISA. The best derivative 
among the 26 derivatives was 30 (IPR-3011). The binding mode of 30 shows that the additional 
moiety fits into a pocket lined by Asn-157, His-166, Leu-168, and Ala-255 on uPAR (Fig. 9D). The 
FP and ELISA inhibition curves of 26 and 30 are shown in Fig. 9E and Fig. 9F, respectively. The 
Ki and IC50 in the FP and ELISA assays for 30 are 2.5 ± 0.3 and 15.5 ± 1.4 µM, respectively. 
Compounds 26 (Fig. 9G) and 30 (Fig. 9H) were tested using microscale thermophoresis to 
assess direct binding to uPAR. The resulting Kd of 26 and 30 towards uPAR were 5.8 ± 1.3 and 
2.0 ± 0.4 µM, respectively, consistent with the FP data for these compounds. Compound 30 and 
several of the other 26 derivatives have limited solubility. Like its parent 26, 30 displayed no 
significant redox activity at 100 µM (Fig. S2). 
The binding mode of 28 shows overlap with Lys-23, Tyr-24, and Phe-25 on uPA (Fig. 
10A). A set of 59 derivatives of 28 were purchased and screened by single concentration FP at 
50 µM (Fig. 10B). The six best compounds, 44-49 (Fig. 10C), were tested in a concentration-
dependent manner using the FP assay (Fig. 10D). While the analogs had Ki values ranging from 
5 to 160 µM, the compounds did not inhibit in the ELISA. The first set of analogs, 44-46, modify 
both the biphenyl and methyl group on the benzimidazole of the parent compound, yielding 
compounds that were less potent than the parent compound. The second set of analogs, 47-49, 
modifies only the methyl group on the benzimidazole. Compound 49 (IPR-3485) lacks the methyl 
group entirely, resulting in threefold weaker inhibition constant than the parent. Compounds 47 
and 48 possess aromatic substituents instead of the methyl group, resulting in Kis of 5 µM in the 
FP assay. The lack of inhibition in the ELISA suggests that the compounds, while robust, may not 
be engaging the right hot spots to disrupt the full protein-protein interaction. 
The binding mode of 29 reveals overlap with Lys-23, Tyr-24, and Phe-25 on uPA (Fig. 
11A). A set of 20 derivatives of 29 were purchased and screened at 50 µM (Fig. 11B). The five 
best compounds, 50-54 (Fig. 11C), were tested at multiple concentrations using FP (Fig. 11D) 
and uPAR•uPAATF ELISA (Fig. 11E). All but 53 (IPR-3235) (FP Ki = 5.6 ± 0.6 µM, ELISA IC50 = 
52.0 ± 4.1 µM) and 54 (IPR-3236) (FP showed no inhibition; ELISA IC50 = 65.3 ± 12.3 µM) had 
limited solubility in the two assays. Compound 29 was tested for direct binding in the MST assay 
and binds to uPAR with a Kd of 22.7 ± 11.5 µM.  
DISCUSSION 
Despite the unique opportunity that hot spots offer to guide the design of small-molecule 
inhibitors of protein-protein interactions, they have seldom been used in rational drug design.  In 
fact, hot spots located on the surface of the protein that bears the target pocket (receptor) have 
been largely ignored in computational screening.  A few studies have used ligand hot spots to 
guide the design of more potent inhibitors, although this strategy has never been used in structure-
based virtual screening of chemical libraries.  Here, we present, to the best of our knowledge, the 
first attempt to develop a systematic approach to use hot spots to identify small-molecule 
inhibitors of tight protein-protein interactions from structure-based virtual screening.  We use the 
tight uPAR•uPA protein-protein interaction as a platform to test these approaches. 
The design of small-molecule inhibitors of protein-protein interactions has primarily 
focused on developing small molecules that bear substituents that mimic the position of amino 
acid side chains of the protein ligand in a protein-protein interaction.  Here, we complement this 
approach by exploring a strategy that searches for small molecules that mimic the binding profile 
of the native protein ligand to the receptor of a protein-protein interaction.  We hypothesize that 
small molecules that mimic the interaction of the native protein ligand to receptor are more likely 
to disrupt tight protein-protein interactions.  To test this hypothesis, we introduced a quantitative 
approach to enable the comparison of the binding profiles of compounds to the binding profile of 
the protein ligand.  We use a bitwise fingerprint to represent the pairwise interactions with amino 
acids on the receptor.  When the ligand (protein or compound) engages a residue above a 
threshold, we assign the bit as ‘1’.  The pairwise binding is based on the decomposition energy 
method that was introduced by Gohlke and co-workers to study the effect of individual amino 
acids on a protein-protein interaction.18  The decomposition energy consists of the intermolecular 
energy between the ligand and each amino acid.  This energy includes van der Waals, 
electrostatic, and polar and non-polar solvation energies.  Following the creation of a fingerprint 
for the native protein ligand, in our case uPA, we used structure-based virtual screening to identify 
small molecules that shared a similar fingerprint.  To do this, we docked a large number of 
compounds to uPAR, and generated fingerprints for all these compounds using the predicted 
binding pose.  Compounds were ranked based on how closely their fingerprint matched the native 
ligand’s (e.g. uPA).  To accomplish this, we borrow from the cheminformatics field and use the 
Tanimoto distance to quantify the similarity between fingerprints.  The top candidates that 
emerged from this screen were purchased and tested for binding to uPAR.  Among them, we 
found one hit, 1 (IPR-2797), that inhibited a fluorescently-labeled peptide with an inhibition 
constant Ki of 7 µM.  Analogs of 1 were purchased, confirming the activity of the parent compound 
and providing an opportunity for structure-activity relationships.  Neither 1 nor its derivatives 
inhibited in our ELISA, which includes the entire protein-protein interaction interface.  This 
suggests that improvements could be made to this method, such as perhaps focusing only on the 
most critical residues on the receptor.  A more stringent threshold for picking interface amino 
acids could make this possible.  Another possibility is that there exists a combination of residues 
that must be engaged to disrupt a protein-protein interaction, and that compound 1 does not 
engage the right combination of hot spots.  Regardless, the compound offers an excellent starting 
point to develop potent small-molecule inhibitors of the tight uPAR•uPA protein-protein 
interaction.  We found the compound to have good solubility, does not react with uPAR, and is 
not redox active.  It is also stable in methanol and buffer as evidenced by LC-MS analysis. 
Another strategy that we followed was driven by the hypothesis that small molecules that 
possess substituents that mimic the position of protein ligand amino acid sidechains will more 
likely disrupt the protein-protein interaction. We resorted to pharmacophore modeling to score 
compounds based on how effectively they overlap with ligand residue sidechains.  This approach 
resulted in more hit compounds than the screen using receptor amino acids alone.  However, 
close inspection of the structure of these compounds revealed potentially problematic groups, 
such as a Betti base in compound 6 (IPR-2496) that could result in unstable compounds, or a 
thiol reactive moiety in compound 10 (IPR-2565) that may lead to adduct formation with 
nucleophilic residues on uPAR.  Among all the compounds, we confirmed that 10 is thiol reactive.  
Compound 6 was unstable, as expected, despite the single-digit inhibition in both the FP and 
ELISA assays for a series of derivatives.  In fact, we confirmed that the activity of the compound 
was due to non-specific reactivity through the synthesis of 18 (IPR-2804), a derivative that lacked 
the Betti base. Despite the lack of obvious unstable or reactive moieties for compound 5 (IPR-
2477), we found it to be unstable and its activity is likely due to assay interference or reactivity 
with assay or protein.  Compounds 8 (IPR-2529) and 9 (IPR-2532) were the most robust 
compounds we identified.  Only compound 9 inhibited in both the FP and ELISA suggesting that 
it could be a good starting point for the development of uPAR•uPA inhibitors.  Its large size, 
however, may make it difficult to optimize.  Compound 8 did not inhibit uPAR•uPA in our ELISA 
suggesting that the compound binds, but it may not effectively mimic uPA hot spots.  It is also 
possible that the compound binds to residues on uPAR that negate the benefits of mimicking uPA 
ligands.  
Finally, we wondered whether the use of interface residues on both uPAR and uPA could 
lead to better inhibitors from virtual screening. We combined our fingerprint and pharmacophore 
methods to rank-order compounds docked to uPAR.  It is interesting that this method led to even 
more hit compounds than using fingerprint or pharmacophore alone.  A total of seven hits were 
identified.  Despite the initial concern that three of the compounds had potentially problematic α,β-
unsaturated carbonyls, such as in 23 (IPR-2986), 24 (IPR-2987), or 27 (IPR-2993), none of the 
compounds were found to be thiol reactive.  One compound had an acylhydrazine moiety that 
could also be unstable at low pH, although our work is done at pH 7 suggesting that the compound 
should be stable.  An interesting feature of these compounds compared to those that emerged 
from using strictly the pharmacophore method is that they had fewer rotatable bonds overall, and 
two compounds, namely 26 (IPR-2992) and 28 (IPR-3089) were fragment-like.  Compound 26 
was particularly interesting as it inhibited, albeit weakly, in both our FP and ELISA assays.  
Starting with 26, we followed an analog-by-catalog approach and purchased several derivatives.  
Among the derivatives, we discovered several compounds, including 30 (IPR-3011), which 
exhibited substantially higher binding affinity than the parent fragment-like compound.  We 
confirmed direct binding of both 26 and 30 using microscale thermophoresis with Kd values that 
were similar to the Kis values measured by FP.  30 also possessed substantially better IC50s 
(single-digit micromolar range) in the disruption of the full uPAR•uPA interaction.  Future 
optimization will focus on improving solubility of these derivative compounds, and exploring 
additional substituents for 26.  The methyl group located on the quinoline ring points towards the 
sidechain of a critical tryptophan hot spot on uPA.  The introduction of moieties that mimic the 
tryptophan sidechain may result in substantially greater potency. 
In sum, we present a new approach to identify small-molecule inhibitors of tight protein-
protein interactions that uses the native ligand binding profile to individual amino acids on the 
receptor. When combined with a pharmacophore approach that uses the native protein ligand 
interface amino acids, we identified robust small-molecule inhibitors of the tight uPAR•uPA.  The 
ligand efficiencies of these compounds were excellent, suggesting that compounds that mimic 
protein ligand side chains and binding profile may overcome the limitation of existing inhibitors. 
To the best of our knowledge, this is the first example of a virtual screen that uses the crystal 
structure of a tight protein-protein interaction and identified single-digit micromolar small-molecule 
inhibitors.  These results suggest that while commercial libraries do not cover chemical space that 
is typical of protein-protein interaction inhibitors, it is possible to identify robust starting points that 
could be used to develop small-molecule inhibitors of tight protein-protein interactions.  The 
results also show that virtual screening is also prone to nuisance compounds as several of the 
small molecules that initially showed promising activity were working through a non-specific 
mechanism.  Finally, it is worth mentioning that small-molecule inhibitors that emerged from this 
work are structurally distinct from inhibitors that we previously identified for uPAR.  We compared 
the structure of compounds 1-54 to our previously reported uPAR•uPA inhibitors IPR-80331 and 
IPR-1110.33, 49 The similarity between these compounds was assessed using atom triplet Daylight 
fingerprints. We find that generally, the Tanimoto similarity between compounds 1-54 and our 
previously described inhibitors range from 0.05 to 0.10. 
MATERIALS AND METHODS 
Virtual Screening. A set of commercially-available compounds from ChemDiv Inc. (San 
Diego, CA), ChemBridge Corporation (San Diego, CA), Life Chemicals (Munich, Germany), 
Princeton BioMolecular Research Inc. (Princeton, NJ), Specs (Zoetermeer, Netherlands), and 
Vitas-M Laboratory Ltd (Hong Kong) were retrieved from ZINC.50 Small molecules in this library 
possessing pan-assay interference compound (PAINS)51 or rapid elimination of swill (REOS)52 
moieties were filtered out using the Canvas package in Schrödinger (Schrödinger LLC, New York, 
NY, 2015). This resulted in a compound library of approximately 5.1 million small molecules. 
Individual MOL2 formatted files were converted to PDBQT format using the prepare_ligand4.py 
script in MGLTools.53  
The structure of the uPAR•uPA complex (PDB ID: 3BT1) was retrieved and prepared using 
Protein Preparation Wizard in Schrödinger.54 Bond orders were assigned, hydrogen atoms were 
added, and disulfide bonds were created. Vitronectin (chain B) was removed and the missing loop 
at residues Arg-83 and Ala-84 were introduced using the Prime module. The resulting structure 
was protonated at pH 7.0 using PROPKA55 and separated into its respective monomeric chains. 
The uPAR structure (chain U) was converted to PDBQT format using the prepare_receptor4.py 
script in MGLTools. 
The compound library was docked to the prepared uPAR structure using AutoDock Vina.53 
The binding pocket was centered at the uPAR•uPA interface with a box with dimensions of 21 Å 
× 21 Å × 21 Å. All other parameters were set to default values. The docked conformations were 
converted back to MOL2 format using in-house Python scripts for additional analysis. 
 uPAR Hot Spots. To find compounds that overlapped with hot-spot residues on uPAR in 
the uPAR•uPA complex, we resorted to a fingerprint approach that utilizes interaction energies 
between the receptor and ligand. We determined the interaction energies of each docked 
compound to individual residues of uPAR using the Generalized Born Surface Area (GBSA) 
method in the Amber14 and AmberTools15 software packages.56 Each docked compound was 
assigned Gasteiger charges and gaff57 atom types using the antechamber program.58 Additional 
force field parameters were generated using the parmchk program. Topology and coordinate files 
for the docked complex and individual receptor and ligand were generated with ff14SB59 and gaff57 
force fields using the tleap program. These topology and coordinate files were used as inputs to 
calculate the free energies and per-residue decomposition energies in the MMPBSA.py script.60 
The MMPBSA.py script was modified to include the missing atom radius for iodine atoms.61 The 
calculation using the Generalized Born (GB) method was performed with sander and Onufriev’s 
GB model.62, 63 Solvent-accessible surface area (SASA) calculations were switched to the 
icosahedron (ICOSA) method, where surface areas are computed by recursively approximating 
a sphere around an atom, starting from an icosahedron. Salt concentration was set to 0.1 M. 
Compounds with combined internal and solvation terms (∆EGBTOT) greater than -5.0 kcal∙mol-1 
were discarded. 
For each docked compound, we generate a one-dimensional array with length equal to 
the total number of residues of the uPAR structure. In this vector, each position corresponds to 
an individual residue of uPAR. Each position is assigned a value of ‘1’ (ON) or ‘0’ (OFF) based 
on the residue decomposition energy at that position and acts as a fingerprint for that compound. 
If the energy at the given residue is less than -1.0 kcal∙mol-1, we assign the position a value of ‘1’. 
Otherwise, we assign the position a value of ‘0’. Hot-spot residues were identified from two 
sources: (i) an experimentally-determined alanine scanning of uPAR from Gårdsvoll and 
coworkers44 (Table S1); and (ii) a previously described molecular dynamics (MD) simulation of 
the uPAR·uPA complex (Table S2).33 Similar to the construction of the compound-specific bitwise 
arrays, we create vectors for each type of fingerprint where each position corresponds to an 
interaction energy of the uPAR•uPA complex. In the vector corresponding to the experimental 
alanine scan, a position was assigned a value of ‘1’ if the ∆∆G at that residue is greater than 1.0 
kcal∙mol-1 and ‘0’ otherwise. In the vector corresponding to the per-residue decomposition 
energies, a position is assigned a value of ‘1’ if the total energy (∆EGBTOT) at that residue is less 
than -1.0 kcal∙mol-1 and ‘0’ otherwise. 
In both fingerprints, only a small portion of uPAR will have favorable binding energies with 
its native ligand uPA. Therefore, we reduce the length of each fingerprint to only include positions 
with ‘1’ bits in the uPAR•uPA complex. For each docked compound, we calculate the Tanimoto 
distance between the fingerprints of the complex and the compound in a bitwise manner. The 
fingerprint of the uPAR•uPA complex consists of only ‘1’ bits. Thus, this distance can be simply 
calculated by summing the number of ‘1’ bits in the compound fingerprint and dividing by the 
length of the fingerprint. Compounds were rank-ordered based on their Tanimoto distance, and 
in cases where compounds had the same Tanimoto distance, we used ∆EGBTOT to rank these 
compounds. 
uPA Hot Spots. A pharmacophore-based approach was used to identify docked 
compounds that overlapped with and mimicked known hot spots on uPA. We used four hot spots 
of uPA at the uPAR•uPA interface: Lys-23, Tyr-24, Phe-25, and Trp-30. For each hot spot residue, 
we defined a pharmacophore hypothesis corresponding to the physiochemical properties of the 
individual residue’s sidechain using the Phase package in Schrödinger.47, 48 Phase has six built-
in types of pharmacophore features: (i) hydrogen bond acceptor, (ii) hydrogen bond donor, (iii) 
hydrophobe, (iv) negative ionizable, (v) positive ionizable, and (vi) aromatic ring. We assigned a 
positive charged feature to the ε-amine on Lys-23 and aromatic rings features to the aromatic 
rings of Tyr-24, Phe-25, and Trp-30. A single pharmacophore feature was assigned to the 
benzene rings of Tyr-24 and Phe-25, while two separate pharmacophores were assigned to the 
pyrrole and benzene rings of the bicyclic indole on Trp-30. We searched for compounds 
containing ligand moieties that matched a corresponding pharmacophore feature. A compound 
that matched either of the two aromatic pharmacophore features on Trp-30 was considered to 
overlap and mimic the residue. All compounds that matched a given pharmacophore was retained 
without sorting compounds by Phase’s internal fitness function. For the aromatic 
pharmacophores, no consideration was given to the angle between the normal vectors of an 
aromatic feature and the orientation of an aromatic ring. All other parameters were set at default 
values. Compounds that matched 3 of the 4 residues were retained. 
Selection of Compounds. The top-ranking compounds following virtual screening using 
uPAR and uPA hot spots were retrieved and clustered using the Canvas package in Schrödinger. 
A hashed binary fingerprint corresponding to atom triplets of Daylight invariant atom types were 
generated for these top-ranking compounds. Compounds were then hierarchically clustered using 
their atom triplet fingerprints and average linkage clustering. The Tanimoto similarity between a 
pair of fingerprints was used as the distance metric. Compounds corresponding to the cluster 
centers from hierarchical clustering were purchased for experimental validation. 
Microtiter-Based ELISA for uPAR•uPA. uPAR without the glycosylphosphotidylinositol 
(GPI) anchor was obtained by a purification process as previously described.64 High-binding 
microplates (Greiner Bio-One, Kremsmünster, Austria) were incubated for 2 h at 4 °C with 100 μL 
of 4 μg∙mL–1 of uPAATF in PBS for immobilization as previously described.31 The plate was washed 
with 0.05% Tween-20 in PBS buffer between each step. A 1:1 mixture of Superblock buffer in 
PBS (Thermo Fisher Scientific, Inc. Waltham, MA) with 0.04 M NaH2PO4 and 0.3 M NaCl buffer 
was used for blocking at room temperature for 45 min. Following removal of the blocking buffer 
and washing, 100 µL of 0.85 nM uPAR in PBS with 0.01% triton X-100 was added with 100 to 0.4 
μM compounds in 1% v/v DMSO. Following incubation for 30 min and subsequent washing steps, 
biotinylated human uPAR antibody (1:3000 dilution of 0.2 mg∙mL–1 BAF807, R&D Systems, 
Minneapolis, MN) in PBS containing 1% bovine serum albumin (BSA) was added to the wells 
(100 μL/well) and incubated for 1 h to allow for the detection of bound uPAR. Following washing, 
streptavidin-horseradish-peroxidase in PBS containing 1% BSA was added to the wells and 
incubated for 20 min. The signal developed in the presence of 3,3’,5,5’-tetramethylbenzidine 
(TMB) in phosphate-citrate buffer (pH 5) and hydrogen peroxide was stopped by adding H2SO4 
solution and was detected using a SpectraMax M5e (Molecular Devices, Sunnyvale, CA). When 
compounds were insoluble and visible precipitation was observed, the data points at the high 
concentrations were not included in the calculation of IC50 values. 
Fluorescence Polarization (FP) Assay. Polarized fluorescence intensities were 
measured using EnVision Multilabel plate readers (PerkinElmer, Waltham, MA) with excitation 
and emission wavelengths of 485 and 535 nm, respectively.31 Samples were prepared in Thermo 
Scientific Nunc 384-well black microplate in duplicates. First, the compounds were serially diluted 
in DMSO and further diluted in 1× PBS buffer with 0.01% Triton X-100 for a final concentration of 
200 – 0.2 μM. Triton X-100 was added to the buffer to avoid compound aggregation. 5 μL of the 
compound solution and 40 μL of PBS with 0.01% Triton X-100 containing uPAR was added to the 
wells and incubated for at least 15 min to allow the compound to bind to the protein. Finally, 5 μL 
of fluorescent AE147-FAM peptide solution was added for a total volume of 50 μL in each well 
resulting in final uPAR and peptide concentrations of 320 nM and 100 nM respectively. The final 
DMSO concentration was 2% v/v, which had no effect on the binding of the peptide. Controls 
included wells containing only the peptide and wells containing both protein and peptide each in 
duplicates to ensure the validity of the assay. A unit of millipolarization (mP) was used for 
calculating percentage inhibition of the compounds. When compounds were insoluble and visible 
precipitation was observed, the data points at the high concentrations were not included in the 
calculation of IC50 values. Inhibition constants were calculated from the IC50 values using the Ki 
calculator available at http://sw16.im.med.umich.edu/software/calc_ki/.  
Microscale Thermophoresis (MST). uPAR was labeled with NT-495 fluorescent dye 
(Nanotemper, Munich, Germany) according to the manufacturer’s instructions. Compounds were 
serially diluted in DMSO and further diluted in PBS buffer with 0.025% v/v Tween-20. 10 µL of 
fluorescently-labeled uPAR and 10 µL of compound solution were combined to final 
concentrations of 40 nM fluorescently-labeled uPAR, 2% v/v DMSO and compound 
concentrations ranging from 200 µM to 0.1 µM. The protein-compound solution was incubated for 
10 min at room temperature in the dark, before being taken up in Monolith NT.115 series standard-
treated capillaries. The capillaries were measured on Monolith NT.115 (Nanotemper, Munich, 
Germany) at 25 ºC, with LED power at 40% and MST power at 40%, and the MST was measured 
for 30 s. The data was analyzed using the “Thermophoresis with T-jump” function within the 
NanoTemper Affinity Analysis version 2.0.2 software (Nanotemper, Munich, Germany). The data 
was then fit with the “Kd Model” function within the software to calculate the Kd. 
(E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium (MSTI) Assay. MSTI assay 
was performed according to the manufacturer’s recommendations (Kerafast, Inc. Boston, MA).46 
A 10 mM solution of acetyl-MSTI was added to 50 mM PBS buffered solution at pH 12.0 with 50% 
v/v methanol in a ratio of 1:10 v/v. After mixing and incubating for 2 min at room temperature, the 
solution was diluted with 50 mM PBS at pH 7.4, containing 0.01% NP-40 and 5% v/v methanol to 
generate a final concentration of 30 µM MSTI at pH 7.4. 19.6 µL aliquots of the MSTI solution was 
dispensed in 384-well flat-bottom black plate and 0.4 µL of 5 mM compounds in DMSO were 
added make a 100 µM final concentration. Unreacted MSTI solution without added compound, 
but with equal amount of DMSO, was used as a negative control, while unactivated acetyl-MSTI 
solution with DMSO was used as a positive control. The plate was then incubated with shaking 
for 30 min at room temperature and the fluorescence intensities were measured using a 
Flexstation 3 plate reader (Molecular Devices, Sunnyvale, CA) at excitation and emission 
wavelengths of 510 and 650 nm, respectively. 
Horseradish Peroxidase-Phenol Red (HRP-PR) Redox Activity Assay. HRP-PR assay 
was performed according to the published protocol.65, 66 In brief, 20 µL of 300 µM compounds in 
3% v/v DMSO in Hank’s balanced salt solution (HBSS) (Cat. No. SH30268.02; HyClone, Logan, 
UT) was dispensed into a 384-well clear, flat-bottomed polystyrene plate (Cat. No. 781101; 
Greiner Bio-One, Monroe, NC). Controls with 3% v/v DMSO and 300 µM H2O2 were dispensed. 
20 µL of 2.4 mM fresh dithiothreitol (DTT) in HBSS was added to each well. For the H2O2 controls, 
20 µL HBSS with no DTT was added. After 5 min incubation at RT, 20 µL solution of 300 µg∙ml-1 
Phenol Red (Cat. No. P-2417; Sigma-Aldrich, St. Louis, MO), 180 µg∙ml-1 HRP (Cat. No. P-2088; 
Sigma-Aldrich, St. Louis, MO) was added. After 20 min incubation at room temperature, the 
absorbance was read at 610 nm on a SpectraMax M5e (Molecular Devices, Sunnyvale, CA). 
High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS). 
Compounds at 200 µM were incubated in methanol, PBS, or 30 µM uPAR in PBS for 1 h at room 
temperature. The samples were injected onto a Kinetex 2.6 µm XB-C18 100 Å column (Cat. No. 
00B-4496-E0; Phenomenox, Torrance, CA) on an Agilent 6130 Quadrupole LC/MS system 
(Agilent, Santa Clara, CA). Compounds 6 (IPR-2496), 12 (IPR-2605), and 29 (IPR-3193) were 
eluted by a linear gradient from Buffer A (H2O) to Buffer B (acetonitrile, 5 mM NH4OAc) over 15 
min. Compounds 1 (IPR-2797), 8 (IPR-2529), 9 (IPR-2532), 26 (IPR-2992), and 28 (IPR-3089) 
were eluted by a linear gradient from Buffer A (H2O, 0.1% formic acid) to Buffer B (acetonitrile, 
0.1% formic acid) over 15 min. Column elution was tracked by UV absorption at 256 nm and the 
masses were detected by positive ion mode.  
SUPPORTING INFORMATION 
Table S1. Hot spots on uPAR of the uPAR•uPA interaction (∆∆G ≥ 1 kcal∙mol-1), adapted 
from Gårdsvoll et al, 2006.44 
Table S2. Residues on uPAR of the uPAR•uPA interaction from per-residue decomposition 
(∆EResidue ≤ -1 kcal∙mol-1) 
Table S3. Candidates identified from the uPAR hot spot virtual screening using alanine 
scanning fingerprints for experimental validation. 
Table S4. Candidates identified from the uPAR hot spot virtual screening using 
decomposition energy fingerprints for experimental validation. 
Table S5. Candidates identified from the combined uPAR•uPA hot spot virtual screening 
using alanine scanning fingerprints for experimental validation. 
Table S6. Candidates identified from the combined uPAR•uPA hot spot virtual screening 
using energy decomposition fingerprints for experimental validation. 
Figure S1. MSTI-based thiol reactivity assay was performed in triplicates at 100 µM 
compound and 30 µM MSTI concentrations. Compound 5 (IPR-2477) showed 
assay interference. Compound 6 (IPR-2496) is unstable and had become inactive 
at the time of measurement. 
Figure S2. Hit compounds and select derivatives from the uPAR-only, uPA-only, and 
combined uPAR•uPA screens were tested for redox reactions using a HRP-PR 
assay at 100 µM. 
Figure S3. Compound stability of hits were tested in methanol, PBS, and in the presence of 
uPAR by HPLC-MS. 
Figure S4. Screening the derivatives of compound 5 (IPR-2477). (A) Derivatives of 5 were 
screened at a single 50 µM concentration via FP assay in duplicates. Further 
pursued hits are highlighted in green. (B) Chemical structures of the pursued 
derivative hits. (C) Concentration-dependent FP assay measuring the inhibition of 
uPAR•AE147-FAM peptide interaction by the derivative compounds. Each 
concentration point is measured in duplicates. (D) Concentration-dependent 
ELISA assay measuring inhibition of uPAR•uPAATF interaction by the derivative 
compounds. Each concentration point is measured in duplicates. (E) MSTI-based 
thiol reactivity assay was performed in triplicates at 100 µM compound and 30 µM 
MSTI concentrations. The reaction might be masked by assay interference, as all 
three compounds are yellow when dissolved in the assay buffer. (F) Compound 
stability was tested in methanol, PBS, and in the presence of uPAR by HPLC-MS. 
All compounds were mixtures in solution, suggesting instability. 
Figure S5. Screening the derivatives of compound 6 (IPR-2496). (A) Chemical structures 
of commercial and synthetic derivatives of 6. (B) Derivatives of 6 were screened 
at a single 50 µM concentration via FP assay in duplicates. Ki and IC50 values are 
calculated from concentration-dependent inhibition by the derivatives in the FP 
assay measuring the inhibition of uPAR•AE147-FAM peptide interaction and the 
concentration-dependent ELISA assay measuring inhibition of uPAR•uPAATF 
interaction. (D) MSTI-based thiol reactivity assay was performed in triplicate at 100 
µM compound and 30 µM MSTI concentrations. Compound 6 is unstable and had 
become inactive at the time of measurement. Compound 18 (IPR-2804) is the only 
non-reactive derivative. (D) uPAR•uPAATF ELISA was modified, where 50 µM 
compound was incubated with the immobilized uPAATF for 30 min and washed off 
prior to adding uPAR and subsequent detection. The assay was performed in 
duplicates and shows that the compounds 6 and 17 (IPR-2665) covalently modify 
and inhibit uPA as well as uPAR. Control is a non-covalent inhibitor of uPAR (IPR-
1109). (E) 17 was tested against TEAD4 and CaVβ3 FP assays to highlight its 
promiscuity. (F) Compound stability was tested in methanol, PBS, and in the 
presence of uPAR by HPLC-MS. HPLC-MS analysis of 6 showed that the 
compound broke down in methanol and PBS buffer, presenting with weak UV 
signals. This confirmed that the compounds were unstable. The total ion count 
chromatogram showed three distinct peaks, the intact 6 and two fragments. 
Figure S6. Concentration-dependent FP assay measuring the inhibition of uPAR•AE147-FAM 
peptide interaction by the derivative compounds of 26 (IPR-2992). Each 
concentration point is measured in duplicates. 
Figure S7. Concentration-dependent ELISA assay measuring inhibition of uPAR•uPAATF 
interaction by the derivative compounds of 26 (IPR-2992). Each concentration 
point is measured in duplicates.  
ABBREVIATIONS USED 
CaVβ3  voltage-dependent L-type calcium channel subunit beta-3 
FP  fluorescence polarization 
GB  Generalized Born 
HRP-RP Horseradish Peroxidase-Phenol Red 
Kd  disassociation constant 
MM-GBSA molecular mechanics generalized Born surface area approach 
MST  microscale thermophoresis 
MSTI  (E)-2-(4-mercaptostyryl)-1,3,3-trimethyl-3H-indol-1-ium 
PAINS  pan-assay interference compound 
PPI  protein-protein interaction 
REOS  rapid elimination of swill 
SAR  structure-activity relationship 
TEAD4 transcriptional enhancer factor TEF-3 
uPAR  urokinase plasminogen activator surface receptor 
uPA  urokinase-type plasminogen activator 
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FIGURE LEGENDS 
Figure 1. Structure of the uPAR•uPA binding pocket (PDB: 3BT1). (A) uPAR is shown in 
a surface representation with residues colored based on hydrophobicity. More 
hydrophobic residues are colored brown while more hydrophilic residues are 
colored green. uPA is colored cyan and shown in cartoon. The sidechain of the 
four hotspots of uPA used in the pharmacophore analysis are shown in stick. (B) 
Experimental alanine scan of the uPAR•uPA binding pocket. The change in free 
energy between the mutated and wild-type complexes (∆∆G) after mutation of the 
residue to alanine is color-coded. (C) Per-residue decomposition energies of the 
uPAR•uPA binding pocket. The total enthalpic contribution of each residue is color-
coded. (D) Features of the pharmacophore model used to identify compounds that 
overlap with and mimic the hot spot residues of uPA. uPAR is shown in the 
background colored in white and shown in cartoon. uPA is shown in transparent 
cyan cartoon, with the five hot spot residues shown in stick. A pharmacophore 
model was used to assign features to four of the five hot spot residues (Ile-28 was 
excluded). The amine on the side chain of Lys-23 was assigned a positive 
ionizable feature (transparent red circle), while the aromatic rings of Tyr-24, Phe-
25, and Trp-30 were assigned aromatic ring features (transparent yellow circles). 
Two separate pharmacophore features were assigned to each of the two rings on 
the indole on Trp-30. 
Figure 2. Workflow for the fingerprint method used to identify compounds that mimic 
interactions in the uPAR•uPA complex. A fingerprint method is used to compare 
how effectively compounds mimic receptor hot spots on uPAR. For each docked 
compound, MM-GBSA is used to calculate the per-residue decomposition 
energies between the compound and uPAR. The per-residue decompositions 
used are used to generate a fingerprint, where each position on the fingerprint 
corresponds to the interaction energy between uPAR and the compound of 
interest. This fingerprint is compared to two separate fingerprints of the native 
ligand uPA. The first uPA fingerprint is from an experimentally-determined alanine 
scanning of uPAR. The second is from the per-residue decomposition of the 
uPAR•uPA complex. Compounds are rank-ordered based on their Tanimoto 
distance with the fingerprints of uPA and ∆EGBTOT. 
Figure 3. A virtual screen utilizing the hot spots of uPAR and validation of hits. (A) 
Residues used in the uPAR fingerprints are colored on the surface of uPAR as 
follows: (i) Experimental alanine scan (orange), (ii) decomposition (pink), (iii) both 
(green). uPA is transparently overlaid in cartoon, with the sidechain of hot spot 
residues in stick. (B) Among the top-ranking 500 compounds from each of the 
fingerprints generated from decomposition energies or experimental alanine 
scanning, the proportion of compounds that overlap with each fingerprint residue.  
(C) Single-concentration FP screen of compounds resulting from the virtual screen 
based on uPAR hot spots. Each compound was screened in duplicate at 50 µM 
concentration. Hit compound 1 (IPR-2797) is highlighted in green. (D) The binding 
mode of 1 in the uPAR•uPA binding pocket. The compound is shown in yellow. 
uPAR is shown in white cartoon, with the sidechain of hot spot residues shown in 
pink stick. uPA is shown in partial transparent cyan cartoon. The sidechain of the 
four hotspots on uPA are shown in stick and colored cyan. (E) Concentration-
dependent FP assay measuring the inhibition of uPAR•AE147-FAM peptide 
interaction by 1. 
Figure 4. Screening the derivatives of compound 1 (IPR-2797). (A) Derivatives of 1 were 
screened at a single 50 µM concentration via the uPAR•AE147-FAM peptide FP 
assay in duplicates. Further pursued hits are highlighted in green. (B) Chemical 
structures of the pursued derivative hits. (C) Concentration-dependent FP assay 
measuring the inhibition of uPAR•AE147-FAM peptide interaction by the derivative 
compounds. Each concentration point is measured in duplicates. At high 
concentrations, some compounds were insoluble and as such the data points were 
omitted from curve-fitting. The compounds displayed no inhibition in the 
uPAR•uPA ELISA assay.  
Figure 5. A virtual screen utilizing four hot spots of uPA and validation of hits. (A) 
Single-concentration FP screen of compounds resulting from the virtual screen 
based on uPA hot spots. Each compound was screened in duplicate at 50 µM 
concentration. Hits that are followed up are highlighted in green while those with 
problematic moieties are highlighted in red. Chemical structures of the highlighted 
molecules are shown above. (B) Co-occurrence of hot spots among all compounds 
that overlapped with at least one hotspot on uPA. (C) Overlap between the 
predicted binding mode of the hit molecules and the uPA hotspots are highlighted. 
FP and microtiter ELISA assays were used to measure the Ki and IC50 of the 
compounds in inhibiting uPAR•AE147-FAM peptide and uPAR•uPAATF 
interactions, respectively. Serial dilution points were measured in duplicates. 
Figure 6. Screening the derivatives of compound 8 (IPR-2529). (A) The virtual screening 
binding mode of 8 in the uPAR•uPA binding pocket. The compound is shown in 
yellow. uPAR is shown in white cartoon, with the sidechain of hot spot residues 
shown in pink stick. uPA is shown in partial transparent cyan cartoon. The 
sidechain of the four hotspots on uPA are shown in stick and colored cyan. (B) 
Derivatives of 8 were screened at a single 50 µM concentration via FP assay in 
duplicates. Further pursued hits are highlighted in green. (C) Chemical structures 
of the pursued derivative hits. (D) Concentration-dependent FP assay measuring 
the inhibition of uPAR•AE147-FAM peptide interaction by the derivative 
compounds. Each concentration point is measured in duplicates. At high 
concentrations, the compounds were insoluble and as such the data points were 
omitted from curve-fitting. (E) Concentration-dependent ELISA assay measuring 
inhibition of uPAR•uPAATF interaction by the derivative compounds. Each 
concentration point is measured in duplicates. At high concentrations, the 
compounds were insoluble and as such the data points were omitted from curve-
fitting. 
Figure 7. Screening the derivatives of compound 9 (IPR-2532). (A) The virtual screening 
binding mode of 9 (IPR-2532) in the uPAR•uPA binding pocket. The compound is 
shown in yellow. uPAR is shown in white cartoon, with the sidechain of hot spot 
residues shown in pink stick. uPA is shown in partial transparent cyan cartoon. The 
sidechain of the four hotspots on uPA are shown in stick and colored cyan. (B) 
Derivatives of 9 were screened at a single 50 µM concentration via FP assay in 
duplicates. Further pursued hits are highlighted in green. (C) Chemical structures 
of the pursued derivative hits. (D) Concentration-dependent FP assay measuring 
the inhibition of uPAR•AE147-FAM peptide interaction by the derivative 
compounds. Each concentration point is measured in duplicates. At high 
concentrations, the compounds were insoluble and as such the data points were 
omitted from curve-fitting. (E) Concentration-dependent ELISA assay measuring 
inhibition of uPAR•uPAATF interaction by the derivative compounds. Each 
concentration point is measured in duplicates. 
Figure 8. A virtual screen utilizing hotspots on both uPAR and uPA. (A) Single-
concentration FP screen of compounds resulting from the virtual screen based on 
uPA hot spots. Each compound was screened in duplicate at 50 µM concentration. 
Hits that are pursued are highlighted in green while those with problematic moieties 
are highlighted in red. Chemical structures of the highlighted molecules are shown 
above. (B) Overlap between the predicted binding mode of the hit molecules and 
the uPA hotspots are highlighted. FP and microtiter ELISA assays were used to 
measure the Ki and IC50 of the compounds in inhibiting uPAR•AE147-FAM peptide 
and uPAR•uPAATF interactions, respectively. Serial dilution points were measured 
in duplicates. (C) MSTI-based thiol reactivity assay was performed in triplicates at 
100 µM compound and 30 µM MSTI concentrations. (D) Compound stability of 26, 
28, and 29 were tested in methanol, PBS, and in the presence of uPAR by HPLC-
MS. 
Figure 9. Testing the derivatives of 26 (IPR-2992) leads to 30 (IPR-3011). (A) The binding 
mode of 26 (IPR-2992) in the uPAR•uPA binding pocket. The compound is shown 
in yellow. uPAR is shown in white cartoon, with the sidechain of hot spot residues 
shown in pink stick. uPA is shown in partial transparent cyan cartoon. The 
sidechain of the four hotspots on uPA are shown in stick and colored cyan. (B) The 
core of 26 was used to identify analogs at 5 positions. Among the analogs 
discovered was 30 (IPR-3011). (C) Derivatives of 26 were screened at a single 50 
µM concentration via the uPAR•AE147-FAM peptide FP assay in duplicates. The 
parent compound 26 is highlighted in orange, while compound 30 is highlighted in 
green. (D) The binding mode of 30 (green) is overlaid on the binding mode of 26. 
The additional ring at R1 allows 30 to bind deeper in the uPAR•uPA pocket. (E) 
Concentration-dependent FP assay measuring the inhibition of uPAR•AE147-FAM 
peptide interaction by 26 and 30. Each concentration point is measured in 
duplicates. At high concentrations, 30 was insoluble and as such the data points 
were omitted from curve-fitting. (F) Concentration-dependent ELISA assay 
measuring inhibition of uPAR•uPAATF interaction by 26 and 30. Each concentration 
point is measured in duplicates. At high concentrations, 30 was insoluble and as 
such the data points were omitted from curve-fitting. (G) MST experiment was 
performed with 40 nM NT-495-labeled uPAR and multiple concentrations of 26. 
MST concentration-response curve of the interaction between uPAR and 26 are 
shown. (H) MST experiment was performed with 40 nM NT-495-labeled uPAR and 
multiple concentrations of 30. MST concentration-response curve of the interaction 
between uPAR and 30 are shown. At high concentrations, 30 is insoluble and the 
high concentration points, in light orange, are omitted from curve fitting. 
Figure 10. Screening the derivatives of compound 28 (IPR-3089). (A) The virtual 
screening binding mode of 28 in the uPAR•uPA binding pocket. The compound is 
shown in yellow. uPAR is shown in white cartoon, with the sidechain of hot spot 
residues shown in pink stick. uPA is shown in partial transparent cyan cartoon. The 
sidechain of the four hotspots on uPA are shown in stick and colored cyan. (B) 
Derivatives of 28 were screened at a single 50 µM concentration via FP assay in 
duplicates. Further pursued hits are highlighted in green. (C) Chemical structures 
of the pursued derivative hits. (D) Concentration-dependent FP assay measuring 
the inhibition of uPAR•AE147-FAM peptide interaction by the derivative 
compounds. Each concentration point is measured in duplicates. At high 
concentrations, the compounds were insoluble and as such the data points were 
omitted from curve-fitting. 
Figure 11. Screening the derivatives of compound 29 (IPR-3193). (A) The virtual 
screening binding mode of 29 in the uPAR•uPA binding pocket. The compound is 
shown in yellow. uPAR is shown in white cartoon, with the sidechain of hot spot 
residues shown in pink stick. uPA is shown in partial transparent cyan cartoon. The 
sidechain of the four hotspots on uPA are shown in stick and colored cyan. (B) 
Derivatives of 29 were screened at a single 50 µM concentration via FP assay in 
duplicates. Further pursued hits are highlighted in green. (C) Chemical structures 
of the pursued derivative hits. (D) Concentration-dependent FP assay measuring 
the inhibition of uPAR•AE147-FAM peptide interaction by the derivative 
compounds. Each concentration point is measured in duplicates. At high 
concentrations, the compounds were insoluble and as such the data points were 
omitted from curve-fitting. (E) Concentration-dependent ELISA assay measuring 
inhibition of uPAR•uPAATF interaction by the derivative compounds. Each 
concentration point is measured in duplicates. At high concentrations, the 
compounds were insoluble and as such the data points were omitted from curve-
fitting. (F) MST experiment was performed with 40 nM NT-495-labeled uPAR and 
multiple concentrations of 29. MST concentration-response curve of the interaction 
between uPAR and 29 are shown. At high concentrations, 29 is insoluble and the 
high concentration points, in light blue, are omitted from curve fitting. 
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compounds. Each concentration point is measured in duplicates. (D) Concentration-dependent 
ELISA assay measuring inhibition of uPAR•uPAATF interaction by the derivative compounds. Each 
concentration point is measured in duplicates. (E) MSTI-based thiol reactivity assay was 
performed in triplicates at 100 µM compound and 30 µM MSTI concentrations. The reaction might 
be masked by assay interference, as all three compounds are yellow when dissolved in the assay 
buffer. (F) Compound stability was tested in methanol, PBS, and in the presence of uPAR by 
HPLC-MS. All compounds were mixtures in solution, suggesting instability. 
Figure S5. Screening the derivatives of compound 6 (IPR-2496). (A) Chemical structures of commercial 
and synthetic derivatives of 6. (B) Derivatives of 6 were screened at a single 50 µM concentration 
via FP assay in duplicates. Ki and IC50 values are calculated from concentration-dependent 
inhibition by the derivatives in the FP assay measuring the inhibition of uPAR•AE147-FAM peptide 
interaction and the concentration-dependent ELISA assay measuring inhibition of uPAR•uPAATF 
interaction. (D) MSTI-based thiol reactivity assay was performed in triplicate at 100 µM compound 
and 30 µM MSTI concentrations. Compound 6 is unstable and had become inactive at the time 
of measurement. Compound 18 (IPR-2804) is the only non-reactive derivative. (D) uPAR•uPAATF 
ELISA was modified, where 50 µM compound was incubated with the immobilized uPAATF for 30 
min and washed off prior to adding uPAR and subsequent detection. The assay was performed 
in duplicates and shows that the compounds 6 and 17 (IPR-2665) covalently modify and inhibit 
uPA as well as uPAR. Control is a non-covalent inhibitor of uPAR (IPR-1109). (E) 17 was tested 
against TEAD4 and CaVβ3 FP assays to highlight its promiscuity. (F) Compound stability was 
tested in methanol, PBS, and in the presence of uPAR by HPLC-MS. HPLC-MS analysis of 6 
showed that the compound broke down in methanol and PBS buffer, presenting with weak UV 
signals. This confirmed that the compounds were unstable. The total ion count chromatogram 
showed three distinct peaks, the intact 6 and two fragments. 
Figure S6. Concentration-dependent FP assay measuring the inhibition of uPAR•AE147-FAM peptide 
interaction by the derivative compounds of 26 (IPR-2992). Each concentration point is measured 
in duplicates. 
Figure S7. Concentration-dependent ELISA assay measuring inhibition of uPAR•uPAATF interaction by the 
derivative compounds of 26 (IPR-2992). Each concentration point is measured in duplicates.  
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Arg-25 2.72 6.95 2.56 1.00 
Leu-55 3.02 9.04 3.00 1.09 
Tyr-57 1.78 6.23 3.49 1.18 
Leu-66 2.26 10.6 4.70 1.35 
Ser-100 4.06 13.1 3.24 1.14 
Asp-102 5.07 40.4 7.96 1.66 
Leu-113 6.78 37.0 5.45 1.44 
Asp-140 3.79 15.5 4.10 1.28 
Asp-141 2.58 6.97 2.70 1.03 
Gly-146 3.08 11.7 3.80 1.23 
Gly-148 4.05 21.2 5.23 1.41 
Leu-150 8.41 64.0 7.61 1.64 
Phe-165 1.74 4.84 2.77 1.05 
His-166 3.40 8.87 2.61 1.00 
Met-219 2.11 5.50 2.61 1.01 
 
aGårdsvoll, H.; Gilquin, B.; Le Du, M. H.; Ménèz, A.; Jørgensen, T. J.; Ploug, M., Characterization of the 
Functional Epitope on the Urokinase Receptor. Complete Alanine Scanning Mutagenesis Supplemented by 
Chemical Cross-Linking. J. Biol. Chem. 2006, 281, 19260-19272.  
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Asn-9 -1.19 ± 0.04  2.96 2.27 0.77 0.30 
Thr-27 -2.14 ± 0.01  3.12 6.69 2.14 0.90 
Val-29 -2.37 ± 0.01  1.60 2.45 1.54 0.70 
Leu-31 -1.69 ± 0.01  2.24 1.75 0.78 0.31 
Leu-38 -1.94 ± 0.01  2.46 2.74 1.11 0.53 
Leu-40 -2.25 ± 0.02  2.24 4.38 1.96 0.85 
Arg-53 -3.33 ± 0.02  4.22 8.68 2.06 0.87 
Leu-55 -1.60 ± 0.01  3.02 9.04 3.00 1.09 
Leu-66 -3.93 ± 0.01  2.26 10.6 4.70 1.35 
Glu-68 -2.08 ± 0.04  3.37 1.67 0.50 0.04 
Thr-127 -2.79 ± 0.05  4.13 10.3 2.50 0.99 
Lys-139 -2.99 ± 0.04  2.02 2.63 1.31 0.61 
Asp-140 -2.09 ± 0.08  3.79 15.5 4.10 1.28 
Leu-150 -1.77 ± 0.01  8.41 64.0 7.61 1.64 
His-166 -1.93 ± 0.04 3.40 8.87 2.61 1.00 
Asp-254 -1.08 ± 0.02 2.72 1.39 0.51 0.06 




Table S3. Candidates identified from the uPAR hot spot virtual screening using alanine scanning fingerprints for experimental validation. 


































































IPR-2775 c1cc(Cl)ccc1CNS(=O)(=O)c2c(cn(C)c2)S(=O)(=O)NCc3ccc(Cl)cc3 0.333 -19.6                
IPR-2777 CCCCN1CC(CC1=O)C(=O)Nc(s2)nnc2CSc3ccccc3 0.267 -26.7                
IPR-2786 CCOC(=O)c1ccc(cc1)N(C2c(cc3)ccc3C)C(=O)c(c24)[nH]nc4-c5ccccc5 0.267 -31.2                
IPR-2787 o1cccc1CNc(n2C)nc(c23)n(C)c(=O)n(c3=O)Cc4ccccc4 0.267 -24.8                
IPR-2788 CC(C)(C)CC(=O)N(CCN(C)C)Cc1cnc(n1CC(C)C)S(=O)(=O)Cc2ccccc2 0.333 -14.5                
IPR-2789 c1cnccc1CNC(=O)c2cc(n(n2)C(CC3)CS3(=O)=O)-c(cc4)ccc4C 0.333 -6.9                
IPR-2790 COc(cc1)cc(c12)sc(n2)-n(nc3C)c(c34)NC(=O)CC4c5ccccc5 0.267 -28.3                
IPR-2791 o1cccc1CNC(=O)Cn(nc2)c(=O)c3n(c(c4c23)cccc4)Cc5c(F)cccc5 0.267 -27.9                
IPR-2792 COc(cc1)ccc1NC(=O)c(nc(c23)cccc3)nc2Nc4ccccc4 0.267 -27.1                
IPR-2793 C1CC1C(=O)Nc2cc(ccc2)OCc(n3)cc(=O)n(c34)oc(C)c4 0.267 -26.9                
IPR-2794 o1cccc1CNC(=O)CSc(nn2)n(c23)ccn(c3=O)-c4ccc(F)cc4 0.267 -26.8                
IPR-2795 CC(=O)Nc(n1)sc(c12)cc(cc2OC)NC(=O)Nc3c(Br)cccc3 0.267 -26.4                
IPR-2796 c1ccccc1-n(nc2)c(c23)ncnc3N4CCN(CC4)c5ccccc5 0.267 -26.4                
IPR-2797 c1cccc(c12)oc(c2C)C(=O)NCC(c3ccc(Cl)cc3)N4CCN(C)CC4 0.267 -26.3                
IPR-2798 c1ccc(C)cc1CNC(=O)c2nnc(c(c23)cccc3)N(CC4)CCN4c5c(F)cccc5 0.267 -25.3                
IPR-2799 c1ccccc1CNc(c2C#N)oc(n2)-c(o3)ccc3COc4ccc(Br)cc4 0.267 -25.3                
IPR-2805 C#CCOc1ccc(cc1Br)/C=N/NC(=O)C(c1ccccc1)(c1ccccc1)O 0.267 -27.7                
IPR-2806 COCCNC(=O)CSc1ncnc2c1sc(n2)N1CCOCC1 0.267 -26.7                
IPR-2807 Fc1ccc2c(c1)nc(n(c2=O)N)SCc1ccc(cc1)N1CCCC1=O 0.267 -26.6                
IPR-2808 O=C(Nc1cccn2c1nc(c2)c1ccccc1)CSc1nc(N)cc(=O)[nH]1 0.267 -29.2                
IPR-2809 CCOC(=O)C1=C(CSc2nnc(n2C)c2ccnn2C)N(C(=O)NC1c1ccccc1)CC 0.267 -32.0                
IPR-2810 CCOc1cc(CNc2nnnn2C)cc(c1OCc1ccccc1Cl)Br 0.267 -27.8                
IPR-2811 O=C(c1cccs1)OCC#CCSc1nnc(o1)c1ccccc1 0.267 -25.6                
IPR-2812 COc1cc(ccc1OC(=O)C)C(=O)Nc1cc(Cl)c(c(c1)Cl)O 0.267 -26.0                
IPR-2813 O=C(CC1Cn2ncnc2NC1=O)Nc1ccc(c(c1)C)C 0.267 -24.8                
IPR-2814 COC(=O)CC1N=C(N(C1=O)CCn1c(C)cc(c(c1=O)C#N)C)O 0.267 -26.9                
IPR-2815 NC(=O)C1CCN(CC1)C(=O)c1nn2c(c1)NC(CC2C(F)(F)F)c1ccccc1 0.267 -26.7                
IPR-2816 O=C(Nc1ccc(cc1)Cl)CSc1nc(N)c2c(n1)sc1c2CC(OC1)C(C)C 0.267 -29.7                
IPR-2817 CCc1c(C)c(C#N)c2n(c1N/N=C/c1cc3cc4OCOc4cc3nc1Cl)c1ccccc1n2 0.267 -24.9                
IPR-2818 NC(=O)C1CCN(CC1)c1nc2c(n1CCSc1nc3c([nH]1)cccc3)c(=O)n(c(=O)n2C)C 0.267 -30.3                




Table S4. Candidates identified from the uPAR hot spot virtual screening using decomposition energy fingerprints for experimental validation. 





































































IPR-2771 n1onc(c1N)-n(nn2)c(C)c2C(=O)N\N=C\c3cc(Cl)ccc3 0.353 -30.4                  
IPR-2772 c1cc(Cl)cc(c1C)N(C)C(=O)c2nn(-c3ccc(cc3)OC)c(=O)c4n(C)c(c5c24)cccc5 0.353 -27.6                  
IPR-2773 c1cccc(OC)c1NC(=O)CSc(n2)n(c(=O)c(c23)scc3)-c4ccc(cc4)OC 0.353 -26.4                  
IPR-2774 COc(cc1)c(OC)cc1C(=O)CC2(O)C(=O)N(c(c23)cccc3)Cc4ccccc4 0.353 -19.4                  
IPR-2776 o1cccc1C(=O)N(C(C)C)Cc2csc(n2)COc3c(Cl)ccc(Cl)c3 0.353 -29.5                  
IPR-2778 COCCC(=O)N(CC1)CCC1c(n2)oc(C)c2C(=O)N3CCSCC3 0.353 -26.7                  
IPR-2779 CC(C)NC(=S)N(CC)Cc1cnc(n1CC(C)C)S(=O)(=O)Cc2ccccc2 0.353 -25.7                  
IPR-2780 c1ccccc1OC(C)c2nc(no2)-c(cc3)cc(c34)n(C)cn4 0.353 -25.5                  
IPR-2781 c1cccc(c12)nnn(c2=O)CC(=O)N3CCN(CC3)Cc4ccccc4 0.353 -24.3                  
IPR-2782 CC(=O)Nc(c(Cl)c1)cc(OC)c1C(=O)Nc2nnc(s2)SCCOC 0.353 -23.0                  
IPR-2783 O=C1CCCN1CCCNC(=O)Cn(nc2)c(=O)c(c2c34)n(c3cccc4)Cc5ccccc5 0.353 -21.6                  
IPR-2784 C1COCCN1C(=O)COc2c(cc(Cl)cc2)S(=O)(=O)NCCOc3c(F)cccc3 0.353 -20.6                  
IPR-2785 O=c1[nH]c(=O)n(C)c(c12)n3c(n2CC(C)C)nnc3-c4ccc(cc4)OC 0.353 -20.4                  
IPR-2820 O=C(Nc1nc2c(s1)cccc2)CSc1nnc(c(=O)[nH]1)C 0.353 -21.1                  
IPR-2821 CCOC(=O)C1=C(CSc2nnc(o2)c2cnn(c2)CC)N(C(=O)NC1c1ccccc1)CC 0.353 -31.4                  
IPR-2822 COCCNC(=O)c1nn2c(c1Cl)nc(cc2C(F)(F)F)c1ccco1 0.353 -28.8                  
IPR-2823 COc1ccccc1OCC(=O)Nc1cccc(c1)c1nc2c(s1)cccc2 0.353 -22.2                  
IPR-2824 COCCSc1nnc(s1)NC(=O)c1cc(Cl)c(cc1OC)NC(=O)C 0.353 -23.0                  
IPR-2825 O=C(c1snnc1C)Nc1ccc(cc1)S(=O)(=O)N(c1ccccc1)c1ccccc1 0.353 -22.9                  
IPR-2826 COc1ccc(c(c1)OC)C(P(=O)(c1ccc(cc1)N(C)C)OCC(C)C)O 0.353 -24.5                  
IPR-2827 N#CCCN1CCN(CC1)Cc1cnc(c2c1cc(o2)c1cc(=O)oc2c1cc1OCOc1c2)C 0.353 -20.1                  




Table S5. Candidates identified from the combined uPAR•uPA hot spot virtual screening using alanine scanning fingerprints for experimental 
validation. 





























































IPR-2990 c1ccc2c(c1)cc(o2)C(=O)NC(=S)Nc3cc(ccc3Cl)c4nc5ccccc5s4 0.267 -13.6                
IPR-2996 COc1ccc(cc1)c2nnc(o2)SCc3c(cccc3Cl)Cl 0.267 -27.1                
IPR-2997 NCCNc1nc2c(n1C)c(=O)n(c(=O)n2C)Cc1ccccc1 0.267 -16.9                
IPR-2999 O=C1CC(Cc2c1cn1nc(nc1n2)c1ccccc1)c1ccccc1 0.267 -22.9                
IPR-3000 CCN(CCCC(NC(=O)c1cc2cccnc2n(c1=O)Cc1ccccc1)C)CC 0.267 -11.6                
IPR-3004 COc1ccc(c(c1)S(=O)(=O)N1CCCC(C1)C(=O)NCc1cccnc1)OC 0.267 -5.9                
IPR-3082 O=C(N1CCOCC1)CSc1nnc(n1C)COc1ccccc1 0.267 -12.8                
IPR-3083 COc1ccc(cc1)c1oc2c(n1)cc(cc2)NC(=S)NC(=O)c1ccccc1F 0.267 -23.9                
IPR-3084 S=C(NC(=O)c1cc2c(o1)cccc2)Nc1ccc2c(c1)nc(o2)c1cccnc1 0.267 -13.4                
IPR-3086 CN1CCN(CC1)C(=O)CN(S(=O)(=O)c1ccccc1)c1ccc(cc1)I 0.267 -9.9                
IPR-3088 O=C(c1ccc2c(c1)C(=O)N(C2=O)Cc1ccccc1)Nc1c[nH]c(=O)[nH]c1=O 0.267 -9.5                
IPR-3090 CCn1c(SCC(=O)Nc2ccccc2Br)nnc1c1ccncc1 0.267 -12.7                
IPR-3093 CCn1c(SC(C(=O)Nc2ccccc2)CC)nnc1c1ccc(cc1)OC 0.267 -20.0                
IPR-3094 COc1ccc(cc1NC(=O)Nc1cccc(c1)NC(=O)C)Cl 0.267 -10.1                





Table S6. Candidates identified from the combined uPAR•uPA hot spot virtual screening using energy decomposition fingerprints for experimental 
validation. 





































































IPR-2986 CC1=C([C@@H](CC(=O)N1)c2cc(c(cc2Br)OC)OC)C(=O)OCCc3ccccc3 0.294 -7.8                  
IPR-2987 COc1ccc(cc1OC)[C@@H]2CC3=C([C@H](Nc4ccccc4N3)c5ccc(cc5)Cl)C(=O)C2 0.294 -18.5                  
IPR-2988 c1cc(sc1)CNC(=O)c2c(c3n(n2)[C@@H](C[C@@H](N3)c4cccs4)C(F)(F)F)Br 0.294 -21.6                  
IPR-2989 Cc1ccc(cc1)n2c(nnc2SCC(=O)N/N=C/c3ccc(o3)C)c4ccccc4 0.353 -6.8                  
IPR-2991 CCOc1ccc(c(c1)C)C(=O)C2=C(C(=O)N([C@H]2c3ccc(cc3)C)Cc4cccnc4)[O-] 0.353 -8.3                  
IPR-2992 Cc1cccc2c1nc(cc2C(=O)N3CCOCC3)c4ccccc4 0.294 -18.0                  
IPR-2993 COc1ccc(cc1)[C@@H]2C3=C(C[C@H](CC3=O)c4cccs4)Nc5ccccc5N2 0.294 -13.7                  
IPR-2994 c1ccc(cc1)c2csc3n2c(nn3)SCC(=O)Nc4nc(sn4)c5ccccc5 0.294 -8.8                  
IPR-2995 CCn1cc(c(=O)c2c1nc(nc2)N3CCN(CC3)C(=S)NCc4ccccc4)C(=O)[O-] 0.294 -10.2                  
IPR-2998 Fc1ccc(cc1)C(=O)c1oc2c(c1NC(=O)c1nn(ccc1=O)c1cccc(c1)Cl)cccc2 0.294 -10.6                  
IPR-3001 O=C(c1nn2c(n1)nc(cc2C(F)(F)F)c1ccco1)N1CCOCC1 0.294 -16.3                  
IPR-3002 CCN(CC)C(=O)c1c[nH]c2ccc(cc2c1=O)S(=O)(=O)N(C)c3ccc(cc3)F 0.294 -5.5                  
IPR-3003 CC1=C([C@H](C2=C(N1)CCCC2=O)c3cccc(c3)Br)C(=O)N4CCOCC4 0.294 -16.7                  
IPR-3085 S=C(NC(=O)c1ccccc1I)Nc1ccc2c(c1)nn(n2)c1ccccc1 0.294 -17.6                  
IPR-3087 O=C(Nc1ccccc1F)CSc1nnc(n1C)c1ccc2c(c1)OCO2 0.294 -22.4                  
IPR-3089 O=C1CC(CN1c1cccc2c1cccc2)c1nc2c(n1C)cccc2 0.294 -6.7                  
IPR-3091 COc1ccc(cc1)CNC(=O)CSc1nnc(n1c1ccc(cc1)F)c1ccccc1 0.294 -9.4                  
IPR-3092 O=C(C1CC(=O)N(C1)c1ccc(cc1)Br)Nc1ncccc1C 0.294 -26.1                  
IPR-3095 O=C(c1c(/N=C/c2ccc(o2)COc2ccc(c(c2)C)Cl)cnn1C)NCc1ccco1 0.294 -21.9                  
IPR-3096 O=C(C(c1ccccc1)Sc1nc2c([nH]1)cccc2)Nc1ccc(cc1)S(=O)(=O)N 0.294 -10.7                  
IPR-3192 NCCCNc1nc2c(n1C)c(=O)n(c(=O)n2C)Cc1ccccc1Cl 0.294 -18.8                  
IPR-3193 Clc1ccccc1Cn1c(nc2c1c(O)nc(=O)n2C)N1CCN(CC1)c1ccccc1 0.353 -27.2                  
IPR-3194 COc1cc(OC)ccc1/C(=C/1\C(=O)C(=O)N(C1c1ccccc1)CCCn1cncc1)/O 0.294 -10.2                  




Figure S1. MSTI-based thiol reactivity assay was performed in triplicates at 100 µM compound and 30 µM MSTI 
concentrations. Compound 5 (IPR-2477) showed assay interference. Compound 6 (IPR-2496) is unstable and 





















Figure S2. Hit compounds and select derivatives from the uPAR-only, uPA-only, and combined uPAR•uPA 










Figure S4. Screening the derivatives of compound 5 (IPR-2477). (A) Derivatives of 5 were screened at a 
single 50 µM concentration via FP assay in duplicates. Further pursued hits are highlighted in green. (B) 
Chemical structures of the pursued derivative hits. (C) Concentration-dependent FP assay measuring the 
inhibition of uPAR•AE147-FAM peptide interaction by the derivative compounds. Each concentration point is 
measured in duplicates. (D) Concentration-dependent ELISA assay measuring inhibition of uPAR•uPAATF 
interaction by the derivative compounds. Each concentration point is measured in duplicates. (E) MSTI-based 
thiol reactivity assay was performed in triplicates at 100 µM compound and 30 µM MSTI concentrations. The 
reaction might be masked by assay interference, as all three compounds are yellow when dissolved in the assay 
buffer. (F) Compound stability was tested in methanol, PBS, and in the presence of uPAR by HPLC-MS. All 





Figure S5. Screening the derivatives of compound 6 (IPR-2496). (A) Chemical structures of commercial and 
synthetic derivatives of 6. (B) Derivatives of 6 were screened at a single 50 µM concentration via FP assay in 
duplicates. Ki and IC50 values are calculated from concentration-dependent inhibition by the derivatives in the FP 
assay measuring the inhibition of uPAR•AE147-FAM peptide interaction and the concentration-dependent ELISA 
assay measuring inhibition of uPAR•uPAATF interaction. (D) MSTI-based thiol reactivity assay was performed in 
triplicate at 100 µM compound and 30 µM MSTI concentrations. Compound 6 is unstable and had become 
inactive at the time of measurement. Compound 18 (IPR-2804) is the only non-reactive derivative. (D) 
uPAR•uPAATF ELISA was modified, where 50 µM compound was incubated with the immobilized uPAATF for 30 
min and washed off prior to adding uPAR and subsequent detection. The assay was performed in duplicates 
and shows that the compounds 6 and 17 (IPR-2665) covalently modify and inhibit uPA as well as uPAR. Control 
is a non-covalent inhibitor of uPAR (IPR-1109). (E) 17 was tested against TEAD4 and CaVβ3 FP assays to 
highlight its promiscuity. (F) Compound stability was tested in methanol, PBS, and in the presence of uPAR by 
HPLC-MS. HPLC-MS analysis of 6 showed that the compound broke down in methanol and PBS buffer, 
presenting with weak UV signals. This confirmed that the compounds were unstable. The total ion count 





Figure S6. Dose-dependent FP assay measuring the inhibition of uPAR•AE147-FAM peptide interaction by the 





Figure S7. Dose-dependent ELISA assay measuring inhibition of uPARATFR•uPAR interaction by the derivative 
compounds of 26 (IPR-2992). Each concentration point is measured in duplicates. 












